2019 American Transplant Congress
Optimal Timing of Hepatitis C Treatment among HIV/HCV Co-Infected End-Stage Renal Disease Patients: Pre vs. Post-Transplant
*Purpose: End-stage renal disease (ESRD) patients co-infected with HCV and HIV have access to effective treatment options for HCV infection. However, they also have access…2019 American Transplant Congress
Multicenter Experience Evaluating Outcomes of HCV-Seropositive Donors to HCV-Seronegative Recipients Liver Transplantation
*Purpose: Grafts from hepatitis C virus (HCV)-seropositive donors can now be considered for liver transplant (LT) due to the advent of direct-acting antiviral agents (DAA).…2019 American Transplant Congress
Hepatitis C Treatment and Transplant Outcomes in Liver Transplant Recipients with Hepatitis C Positive Donors
University of Maryland Medical Center, Baltimore, MD
*Purpose: With direct-acting antivirals for hepatitis C virus (HCV), transplant centers have expanded the donor pool with positive short term outcomes with early HCV treatment.…2019 American Transplant Congress
Real World Impact of HCV Viremic Solid Organs on Waitlist Times
*Purpose: The advent of direct acting antiviral agents (DAAs) has led to a paradigm shift in the approach to hepatitis C (HCV) infected organs. The…2019 American Transplant Congress
Hepatitis C Positive Donor to Negative Recipient Kidney Transplantation: A Single Center Real World Experience
North Shore University Hospital, Manhasset, NY
*Purpose: Several small studies have shown that transplanting a hepatitis C virus (HCV) negative recipient with a HCV positive donor is feasible in a research…2019 American Transplant Congress
Timing, Duration, and Source of Hepatitis C Virus (HCV) Antibodies (Ab) among HCV-Negative Recipients of an Organ from an HCV-Infected Donor
1University of Pennsylvania, Philadelphia, PA, 2Abbott Labs, Chicago, IL
*Purpose: The opioid epidemic has increased the number of deceased donors with active (Ab+/NAT+) or prior (Ab+/NAT-) HCV infection. Increased utilization of these donor organs…2019 American Transplant Congress
Rapid Growth of HCV-Infected Donors for HCV-Uninfected Kidney and Liver Transplant Recipients in the United States
Johns Hopkins University, Baltimore, MD
*Purpose: Several single-center reports of using HCV-viremic organs for HCV-uninfected recipients were recently published in the US. In light of recent DAA introduction, we sought…2019 American Transplant Congress
REHANNA: Renal Transplants in Hepatitis C Negative Recipients with Nucleic Acid Positive Donors with Short Course Direct Acting Antiviral Prophylaxis
Johns Hopkins University School of Medicine, Baltimore, MD
*Purpose: To mitigate the current organ shortage and underutilization of hepatitis C-infected deceased donor (HCV D+) organs, we evaluated the use of HCV D+ kidneys…2019 American Transplant Congress
Renal Outcomes from Expander-1: Pilot Study of HCV+ Donor Kidneys for HCV- Kidney Recipients
*Purpose: Direct acting antivirals (DAAs) have led to high cure rates (>95%) for hepatitis C. Utilization of HCV+ donor kidneys for patients with advanced kidney…2018 American Transplant Congress
Transplanting Kidneys from HCV-Infected Donors into HCV-Negative Recipients: Longer-Term and Extended Results of the THINKER Trial
1University of Pennsylvania, Philadelphia; 2Gift of Life, Philadelphia.
Background: In 2016, 800 kidneys from HCV+ deceased donors were discarded. Short-term (6-month) data from the first 10 subjects in the THINKER-1 trial (NCT02743897; funder:…
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 28
- Next Page »